

PHARMACEUTICAL 2023

Arcturus Therapeutics Holdings Inc. Rank 154 of 446









PHARMACEUTICAL 2023

Arcturus Therapeutics Holdings Inc. Rank 154 of 446



The relative strengths and weaknesses of Arcturus Therapeutics Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcturus Therapeutics Holdings Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 77% points. The greatest weakness of Arcturus Therapeutics Holdings Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 150%, being 107% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	403,333
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	126,984
Liabilities, Non-Current	33,020
Other Assets	34,639
Other Compr. Net Income	0
Other Expenses	1,295
Other Liabilities	20,071
Other Net Income	-1,533
Other Revenues	205,999
Property and Equipment	12,415
Research and Development	147,751
Selling, General and Administrative Expense	46,071

Output Variable	Value in 1000 USD
Assets	450,387
Liabilities	180,075
Expenses	195,117
Revenues	205,999
Stockholders Equity	270,312
Net Income	9,349
Comprehensive Net Income	9,349
Economic Capital Ratio	150%

